[A15-53] Secukinumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Last updated 02.06.2016
Project no.:
A15-53
Commission:
Commission awarded on 14.12.2015 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Muscles, bones and joints
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2016-06-02 A G-BA decision was published.